IDAHO DEPARTMENT OF HEALTH & WELFARE
DIVISION OF PUBLIC HEALTH

Remdesivir Distribution Plan for Idaho
May 27, 2020

Background
The U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization on May 1, 2020, for remdesivir for the treatment of coronavirus disease 2019 (COVID-19). The manufacturer, Gilead Sciences, Inc., has donated a supply of remdesivir for use worldwide, including in the United States. The U.S. Department of Health and Human Services (HHS) is allocating the donated medications to states, who are in turn distributing to hospitals within each state.

The intended use of remdesivir is for adults and children who are hospitalized with suspected or laboratory confirmed COVID-19 and severe disease. Severe disease is defined as having $SpO_2 \leq 94\%$ on room air or requiring supplemental oxygen, mechanical ventilation, and/or extracorporeal membrane oxygenation (ECMO).

Distribution plan in Idaho
On May 12, 2020, Idaho received 10 cases of remdesivir. These cases were distributed to 7 hospitals on May 13, 2020, after contacting hospitals throughout the state likely to care for hospitalized patients with severe COVID-19. At least one hospital in each local public health district received remdesivir (either directly or as part of a health system allocation). Hospitals receiving shipments were instructed that they might be asked to share the medication with other hospitals if an urgent need developed.

Moving forward, the state of Idaho will continue to distribute the state's allocation of donated remdesivir to hospitals caring for or most likely to care for hospitalized patients with severe disease. Regular reports will be made to the Governor's Coronavirus Working Group regarding the distribution.

Minimum criteria for consideration:
- All hospitals with >25 beds (non-critical access hospitals).

Additional criteria for consideration:
- Hospitals currently caring for patients who meet the EUA criteria for treatment with remdesivir.
- Hospitals that have already used remdesivir distributed in the initial allocation.
- Hospitals with no or little available remdesivir from previous allocations.

Rationale:
There are non-critical access hospitals located throughout Idaho. Patients hospitalized with severe illness from COVID-19 will likely be cared for in one of these hospitals; patients with severe disease presenting to or admitted at smaller hospitals would likely be transferred to one of the larger hospitals. In the rare circumstance that a provider in a smaller hospital determined that a patient in their facility would benefit from remdesivir, a request can be made to the state for shipment of a course of treatment from one of the larger nearby hospitals to the smaller hospital.

Allocation plan within hospitals
Given the very small quantity of remdesivir that Idaho has received, the state of Idaho is not currently making recommendations for patient selection for the use of remdesivir beyond the EUA criteria. It is

recommended that hospitals develop protocols for patient selection in consultation with infectious disease experts and pulmonologists/intensivists. If patient need exceeds supply, hospitals may wish to consult with their ethics committees as well.

Other resources

Requests for emergency access to remdesivir on a compassionate use basis are currently accepted by the manufacturer for pregnant women and children less than 18 years of age.

Multiple clinical trials involving remdesivir are currently underway or in development. Please check *ClinicalTrials.gov* for the latest information.

It is anticipated that remdesivir will be available to hospitals through commercial sources by August 2020.

References

FDA, Remdesivir Emergency Use Authorization
https://www.fda.gov/media/137564/download

NIH, COVID-19 Treatment Guidelines (https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/remdesivir/)

Emergency Access to Remdesivir Outside of Clinical Trials
https://www.gilead.com/purpose/advancing-global-health/covid-19/emergency-access-to-remdesivir-outside-of-clinical-trials